AiViva
Developing treatments that change lives
Overview
Raised: $1,025,275
Total Commitments ($USD)
StartEngine
06/17/2022
12/14/2022
$400
Equity - Common
Seed
RegCF
$2.00
$48,772,314
Rolling Commitments ($USD)
12/31/2022
$5,696
425
2020
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$17,000 |
$153,000 |
|
COGS |
$0 |
$0 |
|
Tax |
$4,070 |
$800 |
| ||
| ||
|
Net Income |
$-3,960,872 |
$-4,542,477 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$3,601,734 |
$5,419,620 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$4,583,591 |
$8,589,570 |
|
Short-Term Debt |
$437,051 |
$597,651 |
|
Long-Term Debt |
$23,892 |
$0 |
|
Total Liabilities |
$460,943 |
$597,651 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Founder Profile
AiViva Founder Dr. Diane Tang-Liu on Advancing Medicine
It can be difficult and time-consuming to manage chronic and degenerative conditions. One example is wet age-related macular degeneration (AMD), a condition that causes abnormal blood vessel growth in the eye. These vessels leak fluid and scar the eye, affecting a person’s vision. The treatment for this condition is generally a monthly injection of eye medication.AiViva has developed a treatment for this and other eye, skin, urinary tract, and cancer conditions that would provide more long-term relief. We spoke with AiViva founder and CEO Dr. Diane Tang-Liu about this new treatment and its potential applications.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.